Duopharma Biotech Berhad

KLSE:DPHARMA 株式レポート

時価総額:RM1.2b

このページの翻訳は実験的なもので、現在開発中です。お待ちしております!

Duopharma Biotech Berhad 配当金

配当金 基準チェック /36

Duopharma Biotech Berhad配当を支払う会社であり、現在の利回りは1.85%で、収益によって十分にカバーされています。

主要情報

1.9%

配当利回り

49%

配当性向

業界平均利回り5.8%
次回配当支払日n/a
配当落ち日n/a
一株当たり配当金n/a
一株当たり利益RM0.047
3年後の配当利回り予想2.4%

最近の配当金アップデート

Duopharma Biotech Berhad (KLSE:DPHARMA) Is Due To Pay A Dividend Of MYR0.005

Aug 27
Duopharma Biotech Berhad (KLSE:DPHARMA) Is Due To Pay A Dividend Of MYR0.005

Duopharma Biotech Berhad (KLSE:DPHARMA) Is Paying Out A Dividend Of MYR0.018

Apr 04
Duopharma Biotech Berhad (KLSE:DPHARMA) Is Paying Out A Dividend Of MYR0.018

Duopharma Biotech Berhad (KLSE:DPHARMA) Has Announced A Dividend Of MYR0.005

Aug 18
Duopharma Biotech Berhad (KLSE:DPHARMA) Has Announced A Dividend Of MYR0.005

Recent updates

Duopharma Biotech Berhad (KLSE:DPHARMA) Is Due To Pay A Dividend Of MYR0.005

Aug 27
Duopharma Biotech Berhad (KLSE:DPHARMA) Is Due To Pay A Dividend Of MYR0.005

Duopharma Biotech Berhad (KLSE:DPHARMA) Is Paying Out A Dividend Of MYR0.018

Apr 04
Duopharma Biotech Berhad (KLSE:DPHARMA) Is Paying Out A Dividend Of MYR0.018

Duopharma Biotech Berhad's (KLSE:DPHARMA) Intrinsic Value Is Potentially 24% Below Its Share Price

Feb 17
Duopharma Biotech Berhad's (KLSE:DPHARMA) Intrinsic Value Is Potentially 24% Below Its Share Price

These 4 Measures Indicate That Duopharma Biotech Berhad (KLSE:DPHARMA) Is Using Debt Extensively

Oct 21
These 4 Measures Indicate That Duopharma Biotech Berhad (KLSE:DPHARMA) Is Using Debt Extensively

Duopharma Biotech Berhad (KLSE:DPHARMA) Has Announced A Dividend Of MYR0.005

Aug 18
Duopharma Biotech Berhad (KLSE:DPHARMA) Has Announced A Dividend Of MYR0.005

Calculating The Intrinsic Value Of Duopharma Biotech Berhad (KLSE:DPHARMA)

Aug 07
Calculating The Intrinsic Value Of Duopharma Biotech Berhad (KLSE:DPHARMA)

Duopharma Biotech Berhad's (KLSE:DPHARMA) Shareholders Will Receive A Smaller Dividend Than Last Year

Mar 28
Duopharma Biotech Berhad's (KLSE:DPHARMA) Shareholders Will Receive A Smaller Dividend Than Last Year

Calculating The Fair Value Of Duopharma Biotech Berhad (KLSE:DPHARMA)

Mar 27
Calculating The Fair Value Of Duopharma Biotech Berhad (KLSE:DPHARMA)

We Think That There Are Issues Underlying Duopharma Biotech Berhad's (KLSE:DPHARMA) Earnings

Nov 26
We Think That There Are Issues Underlying Duopharma Biotech Berhad's (KLSE:DPHARMA) Earnings

Need To Know: The Consensus Just Cut Its Duopharma Biotech Berhad (KLSE:DPHARMA) Estimates For 2021

Nov 25
Need To Know: The Consensus Just Cut Its Duopharma Biotech Berhad (KLSE:DPHARMA) Estimates For 2021

Duopharma Biotech Berhad's (KLSE:DPHARMA) Dividend Will Be RM0.005

Aug 20
Duopharma Biotech Berhad's (KLSE:DPHARMA) Dividend Will Be RM0.005

Here's Why Duopharma Biotech Berhad (KLSE:DPHARMA) Can Manage Its Debt Responsibly

May 22
Here's Why Duopharma Biotech Berhad (KLSE:DPHARMA) Can Manage Its Debt Responsibly

Duopharma Biotech Berhad (KLSE:DPHARMA) Investors Should Think About This Before Buying It For Its Dividend

Apr 13
Duopharma Biotech Berhad (KLSE:DPHARMA) Investors Should Think About This Before Buying It For Its Dividend

A Look At The Fair Value Of Duopharma Biotech Berhad (KLSE:DPHARMA)

Mar 14
A Look At The Fair Value Of Duopharma Biotech Berhad (KLSE:DPHARMA)

Duopharma Biotech Berhad (KLSE:DPHARMA) Seems To Use Debt Quite Sensibly

Feb 12
Duopharma Biotech Berhad (KLSE:DPHARMA) Seems To Use Debt Quite Sensibly

Do Institutions Own Duopharma Biotech Berhad (KLSE:DPHARMA) Shares?

Jan 28
Do Institutions Own Duopharma Biotech Berhad (KLSE:DPHARMA) Shares?

Is Duopharma Biotech Berhad (KLSE:DPHARMA) The Right Choice For A Smart Dividend Investor?

Jan 12
Is Duopharma Biotech Berhad (KLSE:DPHARMA) The Right Choice For A Smart Dividend Investor?

決済の安定と成長

配当データの取得

安定した配当: DPHARMAの配当金支払いは、過去10年間 変動性 が高かった。

増加する配当: DPHARMAの配当金支払額は過去10年間減少しています。


配当利回り対市場

Duopharma Biotech Berhad 配当利回り対市場
DPHARMA 配当利回りは市場と比べてどうか?
セグメント配当利回り
会社 (DPHARMA)1.9%
市場下位25% (MY)1.7%
市場トップ25% (MY)4.6%
業界平均 (Pharmaceuticals)5.8%
3年後のアナリスト予想 (DPHARMA)2.4%

注目すべき配当: DPHARMAの配当金 ( 1.85% ) はMY市場の配当金支払者の下位 25% ( 1.65% ) よりも高くなっています。

高配当: DPHARMAの配当金 ( 1.85% ) はMY市場の配当金支払者の上位 25% ( 4.46% ) と比較すると低いです。


株主への利益配当

収益カバレッジ: DPHARMAの 配当性向 ( 48.8% ) はかなり低いため、配当金の支払いは利益によって十分にカバーされます。


株主配当金

キャッシュフローカバレッジ: DPHARMAは合理的な 現金配当性向 ( 55.2% ) を備えているため、配当金の支払いはキャッシュフローによって賄われます。


高配当企業の発掘